Remember That Time Trump Said He “Probably Should” Take Ozempic?

The article highlights a potential connection between Donald Trump and access to an experimental obesity drug, Ozempic, developed by Eli Lilly. The speculation stems from Trump's previous comments about supporting weight-loss drugs and even suggesting that he and his staff should try them. This situation is notable because it underscores the intersection of politics and health, raising questions about access to experimental medications and the influence of high-profile individuals on medical advancements. It's an intriguing glimpse into how personal endorsements can impact public perception and demand for pharmaceutical products.